Akorn, Inc. (NASDAQ:AKRX) has been assigned a consensus recommendation of “Hold” from the ten research firms that are presently covering the company, Marketbeat Ratings reports. Six analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $6.60.

Several research firms have issued reports on AKRX. Zacks Investment Research upgraded Akorn from a “sell” rating to a “hold” rating in a research note on Thursday, December 13th. BidaskClub raised Akorn from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, February 20th. Royal Bank of Canada set a $4.00 target price on Akorn and gave the company a “hold” rating in a research report on Friday, March 1st. Piper Jaffray Companies set a $8.00 target price on Akorn and gave the company a “buy” rating in a research report on Friday, March 1st. Finally, SunTrust Banks assumed coverage on Akorn in a research report on Tuesday, March 19th. They issued a “hold” rating and a $4.00 target price on the stock.

Several large investors have recently bought and sold shares of the business. BlackRock Inc. boosted its stake in shares of Akorn by 43.7% during the 4th quarter. BlackRock Inc. now owns 15,707,461 shares of the company’s stock worth $53,248,000 after acquiring an additional 4,776,900 shares during the period. Vanguard Group Inc. boosted its stake in shares of Akorn by 1.7% during the 3rd quarter. Vanguard Group Inc. now owns 8,545,884 shares of the company’s stock worth $110,926,000 after acquiring an additional 141,746 shares during the period. Vanguard Group Inc boosted its stake in shares of Akorn by 1.7% during the 3rd quarter. Vanguard Group Inc now owns 8,545,884 shares of the company’s stock worth $110,926,000 after acquiring an additional 141,746 shares during the period. Marshall Wace LLP boosted its stake in shares of Akorn by 44.9% during the 3rd quarter. Marshall Wace LLP now owns 2,998,492 shares of the company’s stock worth $38,920,000 after acquiring an additional 929,107 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Akorn by 77.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,648,375 shares of the company’s stock worth $8,978,000 after acquiring an additional 1,153,675 shares during the period. 69.36% of the stock is currently owned by hedge funds and other institutional investors.

Akorn stock traded down $0.12 during mid-day trading on Thursday, hitting $3.12. 1,648,751 shares of the company were exchanged, compared to its average volume of 2,504,148. The company has a debt-to-equity ratio of 1.85, a current ratio of 3.42 and a quick ratio of 2.40. Akorn has a 1-year low of $3.12 and a 1-year high of $19.81. The firm has a market capitalization of $406.88 million, a P/E ratio of -8.67 and a beta of 2.75.

Akorn (NASDAQ:AKRX) last released its quarterly earnings data on Thursday, February 28th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.31). Akorn had a negative return on equity of 13.34% and a negative net margin of 57.91%. The company had revenue of $153.39 million for the quarter, compared to analyst estimates of $164.75 million. During the same quarter in the prior year, the company earned $0.14 earnings per share. The business’s revenue was down 17.6% compared to the same quarter last year. On average, equities research analysts predict that Akorn will post -0.28 EPS for the current fiscal year.

About Akorn

Akorn, Inc, a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health.

Featured Article: Asset Allocation and Your Retirement

Analyst Recommendations for Akorn (NASDAQ:AKRX)

Receive News & Ratings for Akorn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn and related companies with MarketBeat.com's FREE daily email newsletter.